OPIN-2019-0120 To call for ocrelizumab (ocrevus) to be available on the NHS for people living with primary progressive multiple sclerosis (e) Tabled on 24/01/2019

This Assembly:
1. Supports the 21,000 people in the UK who signed the MS Society petition to make ocrelizumab (ocrevus) available on the NHS for people living with primary progressive multiple sclerosis (MS).
2. Recognises that ocrelizumab was licensed by the European Medicines Agency as the first treatment for people with early primary progressive MS in 2017; but this was rejected by the National Institute of Health and Care Excellence (NICE) on the basis of cost.
3. Urges NHS Wales and NICE to do all that they can to make ocrelizumab available for people with primary progressive MS as soon as possible.